• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Mifepristone (Mifeprex) Article and Journal References


List of References

Abortion Pill Used for Tumor Treatment. The Associated Press. 28 August 1993.sedociated Press. 28 August 1993.
Article on David Kessler (title unreadable) The Wall Street Journal. 12 Jan. 1993. A14.
Asch R, Rojas R. The effects of RU486 on the luteal phase of the rhesus monkey. Department of Obstetrics and Gynecology, the University of Texas Health Science Center at San Antonio. 1-17.
Ashok PW, Flett GM, Templeton A. 1998. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet. 352(9127): 542-3.
Ashok PW, Penney GC, Flett GM, Templeton A. 1998. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod. (1O): 2962-5.
Ashok PW, Templeton A. 1999. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. BJOG. 106: 706-10.
Baulieu EE. 1996. The combined use of prostaglandin and antiprogestin in human fertility control. Eur J Obstet Gynecol Reprod Biol. 65(1):115-9.
Baulieu EE. 1997. RU 486 (mifepristone). A short overview of its mechanisms of action and clinical uses at the end of 1996. Ann N Y Acad Sci. 828:47-58
Bertagna X. 1997. Pituitary-Adrenal Response to RU 486 in Man. Psychoneuroendocrinology. 22: 851-855.
Blanch G, Quenby S, Ballantyne ES, et al. 1998. Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study. BMJ. 316(7146):1712-3.
Bokstrom, H; Atterfeit, M.; Alexandersson, M. et. al. 1998. Preoperative Cervical Softening Before First Trimester Legal Abortion by Mifepristone and Misoprostol. Contraception. 58:157-163.
Borgmann CE, Jones BS. 2000. Legal issues in the provision of medical abortion. Am J Obstet Gynecol. 183(2 Suppl): S84-94.
Brain Cancer Patient Gets Approval to Use RU-486. The Washington Post. 30 July 1992. A2
Bygdeman M, Danielsson KG, Swahn ML. 1997. The possible use of antiprogestins for contraception. Acta Obstet Gynecol Scand Suppl. 164:75-7.
Cabezas, E. 1999. Medical Versus Surgical Abortion. International Journal of Gynecology and Obstetrics. 63 Suppl. 1: S141-S146.
Cadepond F, Ulmann A, Baulieu E-E. 1997. RU486 (Mifepristone): Mechanisms of Action and Clinical Uses. Annu. Rev. Med. 48: 129-56.
Cameron S, Kelly R, Critchley H et al. 1997. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertility and Sterility. 67: 1046-53.

Carbonell I, Esteve JL, Velazco A, et al. 1997. Misoprostol 3, 4, or 5 days after methotrexate for early abortion. A randomized trial.

Contraception. 56(3):169-74.

Carbonell JL, Varela L, Velazco A, Cabezas E et al. 1998. Oral methotrexate and vaginal misoprostol for early abortion.

Contraception. 57(2):83-8.

Carney T. Abortion pill test goes awry for one patient. The Des Moines Register. 21 September 1995. 1M, 5M.
Cato ACB, Henderson D, Ponta H. 1987. The hormone response element of the mouse mammary tumour virus DNA, mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. The EMBO Journal. 6: 363-8.
Chan, YF, Ho PC, Ma HK. Blood Loss in Termination of Early Pregnancy by Vacuum Aspiration and by Combination of Mifepristone and Gemeprost. Contraception. 1993; 47: 85-95.
Chang CC, Segal SJ, Bardin WC. 1985. In vivo assessment of anti-progesterone and anti-glucocorticoid activities. The Antiprogestin Steriod RU 486 and Human Fertility Control. 71-8.
Chen X, Xiao B. 1997. Effect of once weekly administration of mifepristone on ovarian function in normal women. Contraception. 56: 175-80.
Chobert MN, Barouki R, Finidori J et al. Antiglucocorticoid properties of ru486 in a differentiated hepatoma cell line. Biochemical Pharmacology. 1-9.
Christin Maitre S, Bouchard P, Spitz, I. 2000. Medical Termination of Pregnancy. The New England Journal of Medicine. 342: 946-956.
Clinical Management Guidelines for Obstetrician-Gynecologists. 1999. Induction of Labor. ACOG Practice Bulletin. 10: 1-9.
Coezy E, Bouhnik J, Clauser E, et al. 1984. Effects of glucocorticoids and antiglucocorticoid on angiotensinogen production by hepatoma cells in culture. In Vitro. 20: 528-34.
Collins R, Hodgen G. 1986. Blockade of the spontaneous midcycle gonadotropin surge in monkeys by ru 486: a progesterone antagonist or agonist? J Clin Endocrinol Metab. 63: 1270-6.
Cooney J, Dinan T. 1996. Type II (glucocorticoid) receptors mediate fast-feedback inhibition of the hypothalamic-pituitary-adrenal axis in man. Life Sciences. 59: 1981-8.
Correction regarding an article on May 5, 1991 about the French abortion drug RU 486. The New York Times. 19 May 1991
Creinin MD, Shulman T. 1997. Effect of nonsteroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. Contraception. 56(3):165-8.
Creinin MD, Vittinghoff E, Schaff E et al. 1997. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol. 90(4 Pt 1): 611-6.
Croxatto HB, Kovacs L, Massai R et al. 1998. Effects of long-term low-dose mifepristone on reproductive function in women. Human Reproduction. 13: 793-798.
Croxatto HB, Massai MR, Salvatierra AM et al. 1996. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters. Contraception. 54: 79-86.
Croxatto HB, Salvatierra AM, Fuentealba B et al. 1998. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Human Reproduction. 13: 3297-302.
Daling JR, Brinton LA, Voigt LF, et al. 1996. Risk of breast cancer among white women following induced abortion. Am J Epidemiol. 144(4): 373-80.
Danielsson KG, Swahn ML, Bygdeman M. 1997. The effect of various doses of mifepristone on endometrial leukemia inhibitory factor expression in the midluteal phase- an immunohistochemical study. Human Reproduction. 12: 1293-7.
Danielsson KG, Swahn ML, Westlund P et al. 1997. Effect of low daily doses of mifepristone on ovarian function and endometrial development. Human Reproduction. 12: 124-131.
Danielsson KG, Westlund P, Johannisson E et al. 1996. Effect of low weekly dose of mifepristone on ovarian function and endometrial development. Human Reproduction. 11: 256-64.
Dockery P, Ismail RMJ, Li TC et al. 1997. The effect of a single dose of mifepristone (RU486) on the fine structure of the human endometrium during the early luteal phase. Human Reproduction. 12: 1778-84.
Doctor, clinic disagree over abortion pill report. The Associated Press. 21 September 1995.
Elliott C, Brennand J, Calder A. 1998. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstetrics & Gynecology. 92: 804-9.
Etul B, Ellertson C, Winikoff B et al. 1999. Side effects of mifepristone misoprostal abortion versus surgical abortion. Contraception. 59: 107-114.
Fact Sheet. Abortion. The Henry J. Kaiser Family Foundation. May, 1999.
Family planners await more data as pro-life activists claim abortion causes breast cancer. Contraceptive Technology. July 1994. 15: 85-89.
FDA Clearing Way for French Abortion Pill. The San Francisco Chronicle. 17 Dec. 1992. Final Edition. A9.
FDA Oks cancer patient’s use of abortion pill. The Chicago Tribune. 30 July 1992. North Sports Final Edition. C18.
FDA Opens Door for RU 486. The Washington Times. 17 December 1992. A4.
Foldesi I, Falkay G, Kovacs L. 1996. Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception. 54: 27-32.
Gazvani MR, Baruah DN, Alfirevic Z et al. 1998. Mifepristone in combination with methotrexate for the medical treatment of tubal pregnancy: a randomized, controlled trial. Human Reproduction. 13: 1987-90.
Germain G, Philibert D, Pottier J et al. 1985. Effects of the antiprogesterone agent ru486 on the natural cycle and gestation in intact cynomolgus monkeys. The Antiprogestin Steriod RU 486 and Human Fertility Control. 155-67.
German regulators approve RU-486 abortion pill for market. The Boston Globe. 7 July 7 1999. City Edition, Pg. A2.
Giacalone PL, Targosz V, Laffargue F, et al. 1998. Cervical ripening with mifepristone before labor induction: a randomized study. Obstetrics & Gynecology. 92: 487-92.
Gianetti V. 1996. Pharmacists’ beliefs about abortion and RU-486. J Am Pharm Assoc. 36: 698-703.
Girard PM, Landman R, Gaudebout C, et al.. 1993. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 328(21):1514-20.
Glasier A, Thong KJ, Dewar M, et al. 1992. Mifepristone (RU 486) compared with high dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med. 327: 1041-1044. (3640-43)
Gold M, Luks D, Anderson M. 1997. Medical options for early pregnancy termination. American Family Physician. 56: 533-8.
Goldberg J, Plescia M, Anastasio G. 1998. Mifepristone (RU 486) current knowledge and future prospects. Arch Fam Med. 7: 219-22.
Gouk EV, Lincoln K, Khari A et al. 1999. Medical termination of pregnancy at 63 to 83 days gestation. BJOG. 106: 535-9.
Gravanis A, Schaison G, George M et al. 1985. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in post menopausal women. J Clin Endocrinol Metab. 60: 156-63.
Grimes D, Cook R. 1992. Mifepristone (RU 486) – An Abortifacient to Prevent Abortion? N Engl J Med. 327: 1088-1090.
Grimes D. 1997. Medical abortion in early pregnancy: a review of the evidence. Obstet Gynecol. 89: 790-6.
Grunberg SM, Weiss MH, Spitz IM, et al. 1991. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 74(6):861-866.
Grunfeld JP, Elroy D, Moura AM, et al. Effect of an antiglucocorticoid steroid on arterial hypertension induced by glucocorticoids in rats. Centre de Recherches Roussel Uclaf.
Guengant JP, Bangou J, Elul B, Ellertson C. 1999. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe. Contraception. 60: 167-72.
Hamm JT, Allegra JC. New hormonal approaches to the treatment of breast cancer. 1991. Crit Rev Oncol Hematol. 11(1):29-41.
Harp J. 1997. Medical abortion: a crossroads for family practice? American Family Physician. 56: 356-64.
Harper C, Winikoff B, Ellertson C et al. 1998. Blood loss with mifepristone-misoprostal abortion: measures from a trial in China, Cuba, and India. International Journal of Gynecology & Obstetrics. 63: 39-49.
Healy D, Chrousos GP, Schulte HM et al. 1985. Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the anticlucocorticoid steroid RU 486: dose response relationships. J Clin Endocrinol Metab. 60: 1-4.
Heikinheimo O, Rapta S, Grunberg S et al. 1997. Alterations in the pituitary-thyroid and pituitary-adrenal axes- consequences of long-term mifepristone treatment. Metabolism. 46: 292-6.
Hermann W, Whyss R, Riondel A et al. 1982. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C.R. Acad. Sci. Paris. 294: 1-9.
Jang JR, Benet LZ. 1997. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. Journal of Pharmacokinetics & Biopharmaceutics. 25: 647-72.
Jensen JT, Astley SJ, Morgan E et al. 1999. Outcomes of suction curettage and mifepristone abortion in the United States. Contraception. 59: 153-9.
Jeremy JY, Dandona P. 1986. Inhibition by hydrocortisone of prostacyclin synthesis by rat aorta and its reversal with ru486. Endocrinology. 119: 681-5.
Jones BS, Heller S. 2000. Providing medical abortion: legal issues of relevance to providers. J Am Med Womens Assoc. 55(3 Suppl): 145-50.
Jost A. 1986. Animal Reproduction. C.R. Acad. Sc. Paris. 303: 1-6.
Jung-Testas I, Baulieu EE. 1984. Anti-steroid action in cultured l-929 mouse fibroblasts. J. serroid Biochem. 20: 301-6.
Koide SS. 1998. Mifepristone: auxiliary therapeutic use in cancer and related disorders. Journal of Reproductive Medicine. 43: 551-60.
Lader L. March 17, 1994. RU-486, made in America. The New York Times.
Lamberts SW, Tanghe HL, Avezaat CJ et al. 1992. Mifepristone (ru486) treatment of meningiomas. Journal of Neurology, Neurosurgery, and Psychiatry. 55: 486-90.
Leksell L. Stereotactic radiosurgery. 1983. J Neurol Neurosurg Psychiatry. 46(9):797-803
Lewin, T. U.S. to Advance Use of the Pill New York Times. 1 July 1996, A1, B6.
Lindefors-Harris BM, Eklund G, Adami HO, et al. 1991. Response bias in a case-control study: analysis utilizing comparative data concerning legal abortions from two independent Swedish studies. Am J Epidemiol. 134(9): 1003-1008.
Louviere, Mark. Group lied when it said abortion bill test resulted in no complications. The Waterloo Courrier. 24 September 1995.
Mahajan DK, London SN. 1997. Mifepristone (ru486): a review. Fertility & Sterility. 68: 967-76.
Mann, Judy. Playing Politics with Our Lives. The Washington Post. 5 August 1992. B11.
Manufacturers Pass on Abortion Pill. The Washington Times. 22 June 1993. A2.
Marketing of Abortion Pill in U.S. is Sought. The Washington Post. 17 December 1992. A12.
Max SR, Thomas JW, Banner C et al. 1987. Glucocorticoid receptor-mediated induction of lutamine synthetase in skeletal muscle cells in vitro. Endocrinology. 120: 1179-83.
Monte FD. 1995. Current management of meningiomas. Oncology. 9: 83-101.
Murphy C. June 12, 1997. Abortion pill’s U.S. sponsor suing Hungarian drug firm. The Washington Post. A03.
Murphy, AA. Does RU Have a Future in Treating Endometriosis and Leiomyomata?
Neiman L, Chrousos G, Kellner C, et. al. 1985. Successful Treatment of Cushing’s Syndrome with the Glucocorticoid Antagonist RU 486. Journal of Clinical Endocrinology and Metabolism. 61: 536-540.
Olson JJ, Beck DW, Schlechte JA, et al. 1987. Effect of the antiprogesterone ru-38486 on meningioma implanted into nude mice. J Neurosurg. 66: 584-7.
Palmer L. FDA poised to approve abortion pill. Chicago Tribune. 5 January 2000. Chicago Sports Final Edition, 8S.
Parrault D, Eisenhauer E, Pritchard K et al. 1996. Phase II Study of the Progesterone Antagonist Mifepristone in Patients with Untreated Metastatic Breast Carcinoma: A National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology. 14: 2709-2712.
Peyron R, Aubeny E, Targosz V, et al. 1993. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 328(21):1509-13.
Philibert D, Moguilewsky M, Mary I, et al. 1985. Pharmacological profile of RU 486 in animals. The Antiprogestin Steriod RU 486 and Human Fertility Control. 49-68.
Push Breast Cancer Drug. The New York Times. 26 December 1991. Late Edition – Final. A24
Rauch M, Loosfelt H, Philibert D et al. 1985. Mechanism of action of an antiprogesterone, RU486, in the rabbit endometrium. Eur. J. Biochem. 148: 213-8.
Recer P. Studies: Abortion pill may halt breast cancer. The Associated Press. 16 February 1991.
Romieu G, Maudelonde T, Ulmann A, et al. 1987. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer. 74(4):455-61.
Rosenfield A. 1993. Mifepristone (RU 486) in the United States. What does the future hold? N Engl J Med. 328(21):1560-1.
Saraiya M, Green CA, Berg CJ, et al. 1999. Spontaneous abortion-related deaths among women in the United States--1981-1991. Obstet Gynecol. 94(2): 172-176.
Sartor O, Figg W. 1996. Mifepristone: antineoplastic studies. Clinical Obstetrics and Gynecology. 39: 498-505.
Sartor, O, Cutler G. 1996. Mifepristone: Treatment of Cushing’s Syndrome. Clinical Obstetrics and Gynecology. 39: 506-512.
Schaff EA, Eisinger SH, Stadalius LS, et al. 1999. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 59(1): 1-6.
Schaff EA, Fielding SL. 2000. A comparison of the Abortion Rights Mobilization and Population Council trials. JAMWA. 55: 137-40.
Schaff EA, Stadalius LS, Eisinger SH, et al 1997. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 44(4): 353-60.
Schoot PVD, Baumgarten R. 1990. Effects of treatment of male and female rats in infancy with mifepristone on reproductive function in adulthood. J. Reprod. Fert. 90: 255-66.
Secchi J, Lecaque D, Tournemine C et al. 1985. Histopharmacology of RU 486. The Antiprogestin Steriod RU 486 and Human Fertility Control. 79-86.
Secchi J, Lecaque D, Tournemine C. 1987. Early glycogenesis in the uterine glandular cells of the rabbit induced by progestins: a quantitative investigation. Cell Tissue Res. 248: 359-64.
Secchi J, Lecaque D. 1984. Effects of progestins and antiprogestins on mitochondria in uterine glandular cells in the rat: a quantitative investigation. Cell Tissue Res. 238: 247-52.
Shaff EA, Eisinger SH, Stadalius LS et al. 1999. Low-dose of mifepristone 200 mg and vaginal misopristol for abortion. Contraception. 59: 1-6.
Shortle B, Dyrenfurth I, Ferin M. 1985. Effects of an antiprogesterone agent, ru-486, on the menstrual cycle of the rhesus monkey. Journal of Clinical Endocrinology and Metabolism. 60: 731-5.
Silver S. June 12, 1997. Abortion pill move to U.S. in jeopardy. The Associated Press. Business news.
Spitz IM, Bardin CW, Benton L et al. 1998. Early pregnancy termination with mifepristone and misoprostol in the United States. The New England Journal of Medicine. 338: 1241-7.
Spitz IM, Bardin CW. 1993. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med. 329(6):404-12.
Stenlund PM, Ekman G, Aedo AR et al. 1999. Induction of labor with mifepristone: a randomized, double-blind study versus placebo. Acta Obstet Gynecol Scand. 78: 793-8.
Sullivan J. June 13, 1997. Another delay in store for French abortion pill on U.S. market. The New York Times. Late Edition: A16.
Suplee C. Hill Holds Heated Hearing on RU 486. The Washington Post. 20 Nov. 1990. Final Edition, A21.
Test of abortion pill as cancer Rx Approved. The Washington Times. 18 Nov. 1993. A5.
The Alan Guttmacher Institute. Facts in Brief. Induced Abortion. @ www. Agi-usa.org/pubs/fb_induced_abort.html
Trupin, S. Induced Abortion. Danforth’s Obstetrics and Gynecology. Philadelphia: J.B. Lippincott Company, 1994. 567-579.
Van de Lely, Aart-Jan, Foeken, Karin, M.D., Van der Mast, Roos C. et al. Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol Receptor Antagonist Mifepristone (RU 486). Annals of Internal Medicine. 1991; 114: 143-144.
Verneuil HD, Deybach JC, Phung P et al. 1983. Study of anaesthetics agents for their bility to elicit porphyrin biosynthesis in chick embryo liver. Biochemical Pharmacology. 32: 1011-18.
Wark J, Gurtler V. Steroid inhibition of calcitriol-induced prolactin production in gh4c1 cells: specificity and sensitivity. University of Melbourne, Department of Medicine, The Royal Melbourne Hospital. 1-15.
Winikoff B, Ellertson C, Elul B, et al. 1998. Acceptability and feasibility of early pregnancy termination by mifepristone-misopristol. Archives of Family Medicine. 7: 360-6.
Winikoff B, Sivin I, Coyaji KJ, et al. 1997. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol. 176(2): 431-437.
Women Satisfied with Abortion Pill. Chicago Sun-Times. 19 July 1998. Late Sports Final Edition, 35.
Zitner A, Savage D. Abortion Pill Could be in the Hands of the Voters. Los Angeles Times. 12 Sept. 2000. Home Edition, E1.